The Lead Episode 112: A Discussion of Brugada Syndrome Ablation for the Prevention of VS Episodes (BRAVE) LIVE from Heart Rhythm 2025 in San Diego-The Lead Episode 112 (video)

Video Transcription

Video Summary

In this Heart Rhythm Society episode, experts discussed the BRAVE trial on Brugada Syndrome ablation to prevent ventricular fibrillation (VF). The randomized trial showed that epicardial ablation significantly reduced VF episodes by 75-80% over three years in high-risk patients with implantable cardioverter-defibrillators (ICDs). However, limitations include its focus on a severe Thai patient population, absence of medication comparison (notably quinidine), and differences in ablation agents. While promising as a potential ICD-sparing therapy for symptomatic high-risk patients, further research comparing ablation with quinidine and clarifying ablation strategies is needed before broader application.

Keywords

Brugada Syndrome

BRAVE trial

epicardial ablation

ventricular fibrillation reduction

implantable cardioverter-defibrillators